Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter

On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026.

Episode metadata supplied by the publisher feed · Published Jul 16, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter

0:00 34:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 34 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on July 16, 2026.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!